Jiangsu Hengrui Medicine announces share buyback for employee stock plan

Jiangsu Hengrui Medicine Co., Ltd. has submitted its Next Day Disclosure Report, revealing a buyback of 907,300 A shares on October 10, 2025. These shares, listed on the Shanghai Stock Exchange, were repurchased for an A-share employee stock ownership plan. The buyback price ranged from RMB 68.05 to RMB 69.66 per share, with a total expenditure of RMB 62,438,293.2.

This transaction represents a 0.0143% change in the company's issued shares (excluding treasury shares) relative to the prior day's closing balance. Before the buyback, the company had 6,365,968,564 issued shares (excluding treasury shares) and 13,033,710 treasury shares. Following the buyback, the number of issued shares (excluding treasury shares) decreased to 6,365,061,264, while treasury shares increased to 13,941,010.

The total issued shares, including treasury shares, remain at 6,379,002,274. The company confirmed that this share repurchase on another stock exchange adhered to the applicable rules for share buybacks in that jurisdiction. The repurchased shares will be held as treasury stock, earmarked for the aforementioned employee stock ownership plan.